文献速递中医内科中药与中成药合理使用中医康复

芪龙胶囊治疗缺血性卒中:前瞻性多中心非随机对照试验

Clinical effectiveness of Qilong capsule in patients with ischemic stroke: A prospective, multicenter, non-randomized controlled trial.
PubMed 文献 · Phytomedicine · 2022-06-15

本研究为前瞻性多中心非随机对照试验,纳入2302例气虚血瘀证缺血性卒中患者,比较芪龙胶囊联合常规治疗与单用常规治疗的疗效。治疗24周后,联合组在改善mRS、NIHSS、气虚证候、血瘀证候、SAS评分及提高BI评分方面均显著优于对照组,且未见严重不良反应。

要点

  • 芪龙胶囊联合常规治疗可改善缺血性卒中患者24周时的神经功能与日常生活能力。
  • 联合治疗在降低mRS、NIHSS、气虚证候、血瘀证候及SAS评分方面优于单用常规治疗。
  • 研究未发现芪龙胶囊导致严重不良反应的证据,但仍需高质量RCT进一步验证。

核心结论

  • 芪龙胶囊联合常规治疗在降低mRS评分、NIHSS评分、气虚证候评分、血瘀证候评分及SAS评分,以及提高BI评分方面优于单用常规治疗。
  • 研究未发现芪龙胶囊治疗缺血性卒中患者引起严重不良反应的证据。
  • 仍需进一步高质量随机对照试验确认上述阳性结果。

研究设计与样本

  • 研究为前瞻性、多中心、非随机对照试验,在中国7家医院开展。
  • 纳入年龄35至80岁、诊断为缺血性卒中且中医辨证为气虚血瘀证的参与者。
  • 共筛选2468例,最终纳入2302例进行分析,其中干预组(芪龙胶囊组)1260例,对照组(非芪龙胶囊组)1042例。
  • 倾向性评分匹配后形成芪龙胶囊组300例与非芪龙胶囊组300例的子样本。
  • 芪龙胶囊干预疗程为12周,两组均接受标准治疗,并在第12周和第24周进行面对面随访。

主要发现

  • 治疗第24周,芪龙胶囊联合常规治疗在降低mRS评分(p < 0.05)、NIHSS评分(p < 0.001)、气虚证候评分(p < 0.01)、血瘀证候评分(p < 0.001)及SAS评分(p < 0.05)方面显著优于单用常规治疗,并显著提高BI评分(p < 0.05)。
  • 子样本中,第12周良好功能结局(mRS评分0至3分)在芪龙胶囊组与非芪龙胶囊组间差异有统计学意义(p < 0.01,97% vs 91.7%)。
  • ART ANOVA显示,考虑交互效应时,芪龙胶囊组mRS(p < 0.01)、BI(p < 0.05)和NIHSS(p < 0.001)的改善优于非芪龙胶囊组。
  • GLMM显示,芪龙胶囊组mRS和NIHSS评分的降低优于非芪龙胶囊组(p < 0.001);倾向性评分匹配后子样本中芪龙胶囊组BI评分增加多于非芪龙胶囊组(p < 0.001)。

关键数值与推荐

  • 主要结局指标包括改良Rankin量表(mRS)、美国国立卫生研究院卒中量表(NIHSS)和Barthel指数(BI)。
  • 次要结局指标包括中医证候(气虚证候评分、血瘀证候评分)、心理指数(抑郁自评量表SDS、焦虑自评量表SAS)、血脂指标、凝血指标、同型半胱氨酸及良好功能结局(mRS 0至3分)。

临床怎么用

  • 对于气虚血瘀证缺血性卒中患者,可考虑在常规治疗基础上联合芪龙胶囊以改善神经功能、日常生活能力及中医证候。
  • 联合治疗可能有助于缓解焦虑情绪,但需结合患者具体情况个体化决策。

局限性

  • 研究为非随机对照试验,尽管采用倾向性评分匹配处理混杂因素,仍可能存在残余混杂。
  • 研究结论仍需进一步高质量随机对照试验确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Qilong capsule (QLC) is a Chinese patented medicine characterized by an equal emphasis on replenishing Qi and activating blood circulation. In 2000, China's FDA approved the use of QLC for ischemic stroke (IS). However, there is not yet much high-quality evidence of the clinical effectiveness of QLC combined with conventional treatment (CT) for IS with Qi deficiency and blood stasis syndrome. PURPOSE: In this study, we conducted a prospective, multicenter, non-randomized controlled trial at 7 hospitals in China to investigate the clinical effectiveness of QLC combined with CT for IS with Qi deficiency and blood stasis syndrome. METHODS: Participants aged 35 to 80 years old diagnosed as IS with Qi deficiency and blood stasis syndrome in TCM were recruited. Participants were treated with QLC (intervention group) or non-QLC (control group). The intervention course of QLC was 12 weeks. All participants in two groups received standard treatment. All participants returned for in-person follow-up visits at the 12th week and 24th week. Primary outcome measures included a modified Rankin Scale (mRS), the National Institute of Health Stroke Scale (NIHSS), and the Barthel Index (BI). Secondary outcome measures included TCM syndromes (Qi deficiency syndrome score, blood stasis syndrome score), psychological index (self-rating depression scale, SDS; self-rating anxiety scale, SAS), blood lipid index, blood coagulation index, homocysteine, and favorable functional outcome (mRS 0 - 3). Multiple imputations were used for any missing data. Propensity score matching (PSM) was used to deal with any confounding factors (age, gender, scale score, etc.). Rank alignment transformation variance analysis (ART ANOVA) and generalized linear mixed model (GLMM) were introduced to improve the scientific and accuracy of repeated measurement data. All statistical calculations were carried out with R 3.6.1 statistical analysis software. RESULTS: A total of 2468 participants were screened from November 2016 to January 2019. Finally, 2302 eligible participants were included in the analysis. There were 1260 participants in the intervention group (QLC group) and 1042 participants in the control group (non-QLC group). After PSM matching, sub-samples of 300 participants in the QLC group and 300 participants in the non-QLC group were finally formed. The final results of clinical effectiveness are the same results shared by the total samples and sub-samples after PSM. In the 24th week after treatment, QLC combined with CT proved to be significantly better than CT alone in reducing the scores of mRS (p < 0.05), NIHSS (p < 0.001), Qi deficiency syndrome (p < 0.01), and blood stasis syndrome (p < 0.001), SAS (p < 0.05), as well as in improving BI score (p < 0.05). The favourable functional outcome (mRS score of 0 to 3 at week 12) was statistically different between QLC and non-QLC group in the sub-samples (p < 0.01, 97% vs 91.7%). The results of the ART ANOVA showed that the improvement of mRS (p < 0.01), BI (p < 0.05) and NIHSS (p < 0.001) in QLC group was better than non-QLC group when the interaction effect was considered. The results of GLMM showed that the reduction of mRS and NIHSS scores of patients in the QLC group were better than those of the non-QLC group (p < 0.001). The BI score of the QLC group in the sub-samples after PSM increased more than the non-QLC group (p < 0.001). There was no evidence showing that QLC can cause serious adverse reactions (ADRs) in treating patients with IS. CONCLUSION: QLC combined with CT was better than CT alone in reducing mRS score, NIHSS score, Qi deficiency syndrome score, blood stasis syndrome score, and SAS score, as well as improving BI score after treatment. Further high-quality RCTs are needed to confirm the positive results. The study protocol was embedded in a registry study that registered in the Clinical Trials USA Registry (registration No. NCT03174535).

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Lyu J, Gao Y, Wei R, et al. Clinical effectiveness of Qilong capsule in patients with ischemic stroke: A prospective, multicenter, non-randomized controlled trial. Phytomedicine. 2022. PMID: 35780589. doi:10.1016/j.phymed.2022.154278

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。